The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) has dropped by -22.84 compared to previous close of 2.32. Despite this, the company has seen a fall of -32.45% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-20 that Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date Cohort 2 enrollment nears completion SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (“Aptevo”) (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced two additional frontline AML patients have achieved remission* within 30 days of treatment in the Company’s RAINIER dose optimization trial evaluating mipletamig in combination with standard of care for patients unfit for intensive chemotherapy. In total, 9 of 10 frontline patients across two trials achieved remission* when receiving the triplet combination of mipletamig + venetoclax + azacitidine (ven/aza).
Is It Worth Investing in Aptevo Therapeutics Inc (NASDAQ: APVO) Right Now?
The 36-month beta value for APVO is at 5.64. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APVO is 1.46M, and currently, shorts hold a 4.11% of that float. The average trading volume for APVO on March 26, 2025 was 57.08K shares.
APVO’s Market Performance
APVO stock saw a decrease of -32.45% in the past week, with a monthly decline of -44.24% and a quarterly a decrease of -60.49%. The volatility ratio for the week is 16.01%, and the volatility levels for the last 30 days are 10.81% for Aptevo Therapeutics Inc (APVO). The simple moving average for the past 20 days is -33.89% for APVO’s stock, with a -81.33% simple moving average for the past 200 days.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at -49.33% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.03% of loss for the given period.
Volatility was left at 10.81%, however, over the last 30 days, the volatility rate increased by 16.01%, as shares sank -41.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.63% lower at present.
During the last 5 trading sessions, APVO fell by -32.45%, which changed the moving average for the period of 200-days by -94.17% in comparison to the 20-day moving average, which settled at $2.71. In addition, Aptevo Therapeutics Inc saw -58.47% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APVO
The total capital return value is set at -2.62. Equity return is now at value -284.28, with -119.36 for asset returns.
Based on Aptevo Therapeutics Inc (APVO), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14.
Currently, EBITDA for the company is -24.6 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
In conclusion, Aptevo Therapeutics Inc (APVO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
